Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 135674, 6 pages
http://dx.doi.org/10.1155/2015/135674
Research Article

SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson’s Disease in Chinese and Australians

1Neuroscience Research Australia and The University of New South Wales, Sydney, NSW 2031, Australia
2Department of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
3Australian School of Advanced Medicine, Macquarie University, Sydney, NSW 2109, Australia
4Institute of Immunology & Infectious Diseases, Murdoch University, Perth, WA 6150, Australia

Received 30 May 2014; Revised 6 August 2014; Accepted 20 August 2014

Academic Editor: Hiroyuki Tomiyama

Copyright © 2015 Yue Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Marras and A. Lang, “Parkinson's disease subtypes: lost in translation?” Journal of Neurology, Neurosurgery and Psychiatry, vol. 84, no. 4, pp. 409–415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. van Rooden, W. J. Heiser, J. N. Kok, D. Verbaan, J. J. van Hilten, and J. Marinus, “The identification of Parkinson's disease subtypes using cluster analysis: a systematic review,” Movement Disorders, vol. 25, no. 8, pp. 969–978, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. M. Wickremaratchi, Y. Ben-Shlomo, and H. R. Morris, “The effect of onset age on the clinical features of Parkinson's disease,” European Journal of Neurology, vol. 16, no. 4, pp. 450–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Greenbaum, A. Rigbi, N. Lipshtat et al., “Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: gene and smoking status interaction,” Parkinsonism and Related Disorders, vol. 19, no. 1, pp. 72–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Sutherland, G. Mellick, C. Sue et al., “A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease,” Neuroscience Letters, vol. 414, no. 2, pp. 170–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Chung, S. M. Armasu, J. M. Biernacka et al., “Genomic determinants of motor and cognitive outcomes in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 18, no. 7, pp. 881–886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Huang, D. B. Rowe, and G. M. Halliday, “Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease,” Journal of Parkinson's Disease, vol. 1, no. 3, pp. 271–276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Ritz, S. L. Rhodes, Y. Bordelon, and J. Bronstein, “α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease,” PLoS ONE, vol. 7, no. 5, Article ID e36199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Wickremaratchi, M. D. W. Knipe, B. S. D. Sastry et al., “The motor phenotype of Parkinson's disease in relation to age at onset,” Movement Disorders, vol. 26, no. 3, pp. 457–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. L. Rhodes, J. S. Sinsheimer, Y. Bordelon, J. M. Bronstein, and B. Ritz, “Replication of GWAS Associations for GAK and MAPT in Parkinson's disease,” Annals of Human Genetics, vol. 75, no. 2, pp. 195–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Simón-Sánchez, C. Schulte, J. M. Bras et al., “Genome-wide association study reveals genetic risk underlying Parkinson's disease,” Nature Genetics, vol. 41, no. 12, pp. 1308–1312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Trotta, I. Guella, G. Soldà et al., “SNCA and MAPT genes: independent and joint effects in Parkinson disease in the Italian population,” Parkinsonism and Related Disorders, vol. 18, no. 3, pp. 257–262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Elbaz, O. A. Ross, J. P. A. Ioannidis et al., “Independent and joint effects of the MAPT and SNCA genes in Parkinson disease,” Annals of Neurology, vol. 69, no. 5, pp. 778–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Peeraully and E. K. Tan, “Genetic variants in sporadic parkinson's disease: East vs west,” Parkinsonism and Related Disorders, vol. 18, supplement 1, pp. S63–S65, 2012. View at Google Scholar · View at Scopus
  15. M. Baker, I. Litvan, H. Houlden et al., “Association of an extended haplotype in the tau gene with progressive supranuclear palsy,” Human Molecular Genetics, vol. 8, no. 4, pp. 711–715, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Liu, Q. Xiao, Y. Wang et al., “Analysis of genome-wide association study-linked loci in Parkinson's disease of Mainland China,” Movement Disorders, vol. 28, pp. 1892–1895, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Mizuta, W. Satake, Y. Nakabayashi et al., “Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson's disease,” Human Molecular Genetics, vol. 15, no. 7, pp. 1151–1158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. P. Donnelly, P. Paschou, E. Grigorenko et al., “The distribution and most recent common ancestor of the 17q21 inversion in humans,” The American Journal of Human Genetics, vol. 86, no. 2, pp. 161–171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. Myers, M. Kaleem, L. Marlowe et al., “The H1c haplotype at the MAPT locus is associated with Alzheimer's disease,” Human Molecular Genetics, vol. 14, no. 16, pp. 2399–2404, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. B. G. Hayesmoore, N. J. Bray, W. C. Cross, M. J. Owen, M. C. O'Donovan, and H. R. Morris, “The effect of age and the H1c MAPT haplotype on MAPT expression in human brain,” Neurobiology of Aging, vol. 30, no. 10, pp. 1652–1656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Myers, A. M. Pittman, A. S. Zhao et al., “The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts,” Neurobiology of Disease, vol. 25, no. 3, pp. 561–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Sun and J. Jia, “The +347 C promoter allele up-regulates MAPT expression and is associated with Alzheimer's disease among the Chinese Han,” Neuroscience Letters, vol. 450, no. 3, pp. 340–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Brockmann, C. Schulte, A. K. Hauser et al., “SNCA: major genetic modifier of age at onset of Parkinson's disease,” Movement Disorders, vol. 28, pp. 1217–1221, 2013. View at Google Scholar
  24. J. Jankovic and A. S. Kapadia, “Functional decline in Parkinson disease,” Archives of Neurology, vol. 58, no. 10, pp. 1611–1615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Sharma, J. P. A. Ioannidis, J. O. Aasly et al., “Large-scale replication and heterogeneity in Parkinson disease genetic loci,” Neurology, vol. 79, no. 7, pp. 659–667, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Xia, H. A. De Rohan Suva, B. L. Rosi et al., “Genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism,” Annals of Neurology, vol. 40, no. 2, pp. 207–215, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. T. R. Gaunt, S. Rodríguez, and I. N. M. Day, “Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’,” BMC Bioinformatics, vol. 8, article 428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Dan, C. Wang, J. Ma et al., “MAPT IVS1+124 C>G modifies risk of LRRK2 G2385R for Parkinson's disease in Chinese individuals,” Neurobiology of Aging, vol. 35, pp. 1780.e7–1780.e10, 2014. View at Google Scholar
  29. L. Yu, J. Huang, D. Zhai et al., “MAPT rs242562 and GSK3B rs334558 are associated with Parkinson's Disease in central China,” BMC Neuroscience, vol. 15, article 54, 2014. View at Google Scholar
  30. J. B. J. Kwok, E. T. Teber, C. Loy et al., “Tau haplotypes regulate transcription and are associated with Parkinson's disease,” Annals of Neurology, vol. 55, no. 3, pp. 329–334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. L. F. Cardo, E. Coto, L. de Mena et al., “A search for SNCA 3′ UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease,” Journal of Molecular Neuroscience, vol. 47, no. 3, pp. 425–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. M. Hadjigeorgiou, G. Xiromerisiou, V. Gourbali et al., “Association of α-synuclein Rep1 polymorphism and Parkinson's disease: Influence of Rep1 on age at onset,” Movement Disorders, vol. 21, no. 4, pp. 534–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Botta-Orfila, M. Ezquerra, P. Pastor et al., “Age at onset in LRRK2-associated PD is modified by SNCA variants,” Journal of Molecular Neuroscience, vol. 48, no. 1, pp. 245–247, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. J. C. Latourelle, N. Pankratz, A. Dumitriu et al., “Genomewide association study for onset age in Parkinson disease,” BMC Medical Genetics, vol. 10, article 98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. D. M. Maraganore, M. de Andrade, A. Elbaz et al., “Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease,” The Journal of the American Medical Association, vol. 296, no. 6, pp. 661–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. J. Chung, J. M. Biernacka, S. M. Armasu et al., “Alpha-synuclein repeat variants and survival in Parkinson's disease,” Movement Disorders, vol. 29, no. 8, pp. 1053–1057, 2014. View at Publisher · View at Google Scholar
  37. K. D. Cronin, D. Ge, P. Manninger et al., “Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain,” Human Molecular Genetics, vol. 18, no. 17, pp. 3274–3285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Chiba-Falek and R. L. Nussbaum, “Effect of allelic variation at the NACP-Rep1 repeat upstream of the α-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system,” Human Molecular Genetics, vol. 10, no. 26, pp. 3101–3109, 2001. View at Google Scholar · View at Scopus
  39. Y. Hu, B. Tang, J. Guo et al., “Variant in the 30 region of SNCA associated with Parkinson's disease and serum α-synuclein levels,” Journal of Neurology, vol. 259, no. 3, pp. 497–504, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. D. G. Hernandez, M. A. Nalls, P. Ylikotila et al., “Genome wide assessment of young onset Parkinson's disease from Finland,” PLoS ONE, vol. 7, no. 7, Article ID e41859, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. C. M. Lill, J. T. Roehr, M. B. McQueen et al., “Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDgene database,” PLoS Genetics, vol. 8, no. 3, Article ID e1002548, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Chu and J. H. Kordower, “Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?” Neurobiology of Disease, vol. 25, no. 1, pp. 134–149, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Vartiainen, P. Pehkonen, M. Lakso, R. Nass, and G. Wong, “Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein,” Neurobiology of Disease, vol. 22, no. 3, pp. 477–486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. M. G. Heckman, A. I. Soto-Ortolaza, N. N. Diehl et al., “Evaluation of the role of SNCA variants in survival without neurological disease,” PLoS ONE, vol. 7, no. 8, Article ID e42877, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. N. M. Kanaan and F. P. Manfredsson, “Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?” Journal of Parkinson's Disease, vol. 2, no. 4, pp. 249–267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Yasuda, Y. Nakata, C. J. Choong, and H. Mochizuki, “Neurodegenerative changes initiated by presynaptic dysfunction,” Translational Neurodegeneration, vol. 2, article 16, 2013. View at Google Scholar
  47. J. Zhou, M. Broe, Y. Huang et al., “Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease,” Acta Neuropathologica, vol. 121, no. 6, pp. 695–704, 2011. View at Publisher · View at Google Scholar · View at Scopus